COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.

Funding Opportunities

NIH has released a new center funding initiative to address chronic diseases associated with health disparities that may be of interest to ACTRI-affiliated researchers. 

UCSD is limited to one application, and submissions are due to NIH by June 10. Research Affairs is expediting internal coordination to enable prospective applicants to meet the LOI deadline and allow more time for full proposal development. Given the tight timeline and scope, we appreciate any help in getting word out. 

If you're aware of investigators who may be interested in leading a center proposal, would you consider sharing details below?  

Of note:

  • This NIMHD-led initiative will fund 8-9 regional centers and one coordinating center, each with direct costs up to $15M/5y
  • Proposals will reflect multi-institution collaborations addressing unique combinations of chronic conditions, health disparity population(s), and geographic region
  • Examples of chronic diseases include: obesity, diabetes, hypertension, coronary heart disease, congestive heart failure, asthma, chronic kidney disease, chronic liver disease, stroke, osteoarthritis, and certain cancers
  • Interventions of interest include, but are not limited to:
    • Interventions that are tested or evaluated across the entire region rather than a single location within the region.
    • Multi-sectoral interventions that involve collaboration across different types of organizations in the public and private sectors, such as health, public health, education, labor, housing, transportation, recreation, commerce, water, agriculture, energy, and criminal justice.
    • Interventions that reduce disparities in incidence, morbidity, or mortality of co-occurring chronic health conditions
    • Interventions that reduce multiple common risk factors 
    • Interventions that address multi-generational transmission of chronic disease risk and protective factors
    • Interventions that address structural racism and discrimination 
    • Intervention strategies to identify and test pragmatic, multi-level implementation strategies which leverage the characteristics of the community to achieve sustainable solutions
    • Multi-level interventions that reduce disparities related to access to, utilization of health care services and quality of care 
    • Interventions that reduce preventable hospital admissions and readmissions
  • Centers must Include an Administrative Core, Investigator Development Core, Community Engagement Core, and 3 synergistic R01-level research projects
  • Proposals should leverage existing NIH- or other federally- funded cohorts, networks, and/or consortia

The Research Development team welcomes any questions about internal process at

Center for Medicinal Cannabis Research Grants Program 2021 RFA

Pfizer Global Medical Grants RFPS: 

Transthyretin Cardiac Amyloidosis Fellowship

Application Due Date: June 15, 2021
Specific Area of Interest: It is our intent to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis.

Local Level Educational Grants Program to Increase Awareness & Understanding of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Application Due Date: 2021 application windows - please see RFP for details
Specific Area of Interest: Projects that will be considered for Pfizer support will include local/community activities that focus on improving the care of patients by: 

  • Educating [HCPs] to increase awareness and enable appropriate patient identification by closing knowledge gaps in disease epidemiology, pathophysiology, diagnosis, and emerging treatment paradigms. 
  • Addressing barriers to appropriate diagnosis and strategies that reduce burdens for patients and providers along the pathway to appropriate diagnosis 
  • Exploring strategies that empower patients to play an active role in understanding TTR amyloidosis and decision making regarding available diagnostic and treatment options 
  • Increasing awareness of the changing epidemiology of TTR amyloidosis with a focus on the prevalence of hereditary ATTR and wild-type ATTR subtypes as the science continues to evolve 
  • Increasing awareness of at risk and undiagnosed populations with TTR amyloidosis with a focus on improving strategies that facilitate the appropriate diagnosis of patients early in the disease course before overt cardiomyopathy has ensued [e.g. populations with electrical disturbances, valvular disease, orthopedic manifestations, and cardio-oncology diseases (i.e. Light Chain Amyloidosis)] 
  • Increasing awareness of bone radiotracer scintigraphy as a non-invasive alternative to invasive endomyocardial biopsy for the appropriate diagnosis of TTR cardiac amyloidosis in select patients 
  • Supporting the dissemination of information related to the pharmacologic and non-pharmacologic management of ATTR-CM 
  • Addressing geographic and racial healthcare disparities 
  • Addressing challenges to appropriate diagnoses and caring for patients during an era of increased telehealth utilization 
  • Supporting the development of cardiac amyloid centers that provide leadership, best practices, support and/or training of HCPs within a multidisciplinary team environment in order to improve the quality of care for cardiac amyloidosis patients.